A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea, administered intravitreally, in patients with neovascular age-related macular degeneration.
Research Grant
Administered By
Ophthalmology
Awarded By
Hexal AG
Start Date
October 29, 2020
End Date
July 31, 2023
Administered By
Ophthalmology
Awarded By
Hexal AG
Start Date
October 29, 2020
End Date
July 31, 2023